. Author manuscript; available in PMC: 2020 May 22.

Published in final edited form as: Clin J Oncol Nurs. 2012 Apr;16(2):195–204. doi: 10.1188/12.CJON.195-204

TABLE 1.

ISCL/EORTC Revision to the Staging of Mycosis Fungoides and Sézary Syndrome

Stage	T	N	M	B
IA	1	0	0	0, 1
IB	2	0	0	0, 1
II	1, 2	1, 2	0	0, 1
IIB	3	0–2	0	0, 1
III	4	0–2	0	0, 1
IIIA	4	0–2	0	0
IIIB	4	0–2	0	1
IVA₁	1–4	0–2	0	2
IVA₂	1–4	3	0	0–2
IVB	1–4	0–3	1	0–2

B—blood; EORTC—European Organisation for the Research and Treatment of Cancer; ISCL—International Society for Cutaneous Lymphomas; M—visceral; N—node; T—tumor

Note. From “Revisions to the Staging and Classification of Mycosis Fungoides and Sézary Syndrome: A Proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC),” by E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim, R. Knobler, … S. Whittaker, 2007, Blood, 110, p. 1719. Copyright 2007 by the American Society of Hematology. Reprinted with permission.